The following is a summary of “Complete surgical myocardial revascularization in patients with declined renal functions: 12-month outcomes,” published in the September 2023 issue of Cardiology by Kaya et al.

Researchers started a retrospective study to assess the feasibility and effectiveness of coronary artery bypass grafting (CABG) in multi-vessel disease (MVD)-CAD patients with CKD.

They conducted statistical analysis to assess overall survival using Kaplan-Meier with the log-rank test. From 2020 to 2022, 58 patients underwent on-pump coronary artery bypass grafting surgery for complete myocardial revascularization.

The results showed that the mean age of the cohort was 60.7. Additionally, a high prevalence of medical conditions was observed among the participants, including hypertension (50.0%), diabetes (50.0%), and anemia (41.4%). Intraoperatively, 5.2% of cases experienced low cardiac output syndrome, while perioperative outcomes indicated the need for transfusions in 53.5% of cases and an in-hospital mortality rate of 3.4%. During the 12-month follow-up, there was no need for redo revascularization or renal replacement therapy, but cardiac mortality was 5.2%, and all-cause mortality was 6.9%.

Investigators concluded that complete revascularization is safe and beneficial for patients with CKD, but further research is needed to optimize techniques.

Source: bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-023-03507-1